Polivy Survival Data from Key Trials
Polivy (polatuzumab vedotin), combined with bendamustine and rituximab (BR), improved median overall survival to 12.4 months versus 8.7 months with BR alone in the Phase 3 POLARIX trial for previously untreated diffuse large B-cell lymphoma (DLBCL). This reflects a 3.7-month absolute increase.[1]
In relapsed/refractory DLBCL, the Phase 2 trial showed median overall survival of 12.4 months with Polivy plus BR, compared to 8.7 months historically with BR alone—a similar 3.7-month gain.[2]
Progression-Free Survival Gains
POLARIX reported median progression-free survival of 17.8 months with Polivy-BR versus 10.3 months with BR alone, a 7.5-month increase. At 2 years, 45% of Polivy patients remained progression-free versus 26% on BR.[1]
How This Compares to Standard Care
Standard R-CHOP yields median overall survival over 5 years in fit, untreated DLBCL patients, but Polivy-BR targets higher-risk cases or relapses where survival drops sharply. The 3.7-month OS boost positions Polivy as a second-line option, approved by FDA in 2019 for relapsed cases and 2023 for first-line high-risk use.[3]
Patient Factors Affecting Survival Increase
Gains vary by age, IPI score, and double-hit status. In POLARIX, benefits held across subgroups, but elderly patients (>75) saw smaller absolute gains (2-3 months OS). Real-world data mirrors trial results, with 40-50% response rates in heavily pretreated patients.[1][4]
Ongoing Trials and Future Expectations
Phase 3 trials like POLARGO (vs. G-CHOP) and ZUMA-19 (with CAR-T) test Polivy combos, potentially extending survival to 18+ months in frontline settings. No data yet on long-term cures.5
[1]: FDA Polivy Label
[2]: Sehn et al., Lancet Oncology (2019)
[3]: Genentech Press Release
[4]: ASCO Abstract 2023